How should we manage stable angina in the older adult population?
We discuss:
✅Clinical phenotypes of older adults with SIHD
✅Current evidence on medical therapy and revascularization
✅"Consider, Listen, Decide" framework for treatment decisions
https://t.co/GccNHavS9X
Many older adults undergo complex Percutaneous Coronary Intervention (PCI), but little is known about outcomes in this group.
In this cohort study, confounding notwithstanding, those undergoing complex PCI had poorer outcomes. #AHAJournals@MichaelGNanna https://t.co/5Tv03tHey9
Complex Percutaneous Coronary Intervention Outcomes in Older Adults: @JAHA_AHA
🥸: Good morning!
🥸: So, I wanted to summarize something else today, but this original manuscript just came out.
😱CHIP in older adults led by @MichaelGNanna
Amazing!!!
Let's do it 👇👇👇
Dr. Silvia Vilarinho & Dr. Stephen Wang received awards at @YaleMed's 2023 commencement.
Vilarinho received the Leah Lowenstein Award & Wang received the Betsy Winters House Staff Award.
Read more about the honors ⬇️
@VilarinhoSilvia@StephenWangMD
https://t.co/YbahE03F3e
How should we manage stable angina in the older adult population?
We discuss:
✅Clinical phenotypes of older adults with SIHD
✅Current evidence on medical therapy and revascularization
✅"Consider, Listen, Decide" framework for treatment decisions
https://t.co/GccNHavS9X
Management of Stable Angina in the Older Adult Population: @CircIntv
- This time I get to summarize our work led by my friend @MichaelGNanna
20-point summary 🧵
👇👇👇
We are thrilled to welcome our newest class of fellows starting July 2023! Such a fantastic group! Welcome to the team and we look forward to working with you!
In #ALLHAT, we found no significant differences between chlorthalidone, lisinopril, or amlodipine on death, CHD, and stroke in ISH or IDH. BP lowering, not agent type, is key to #CVD risk reduction. Very grateful for incredible mentorship from @MichaelGNanna!
In Press: Choice of Antihypertensive Agent in Isolated Systolic Hypertension and Isolated Diastolic Hypertension: A Secondary Analysis of the ALLHAT Trial. https://t.co/SrLLkBjLtM
@MichaelGNanna#CardioTwitter#hypertension
@rohan_khera & co-authors:
👉 policy changes needed to reduce HF drug cost
👉 burden of high HF drug costs must be recognized by clinicians
👉 clinicians must balance limiting financial toxicity while maximizing benefit of #GDMT@YaleCardiology@JCardFail
https://t.co/6CHWck6iLE
A study led by @rohan_khera finds a significant number of US families face financial challenges due to atherosclerotic cardiovascular disease #ASCVD, a set of health conditions caused by plaque buildup in arterial walls.
Read more ➡️ https://t.co/QMTk81pgEB
@YaleMed@YaleIMed